Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

March 19, 2024

Study Completion Date

March 19, 2024

Conditions
Joint Infection
Interventions
DRUG

PLG0206

PLG0206 is an engineered antibacterial peptide (EAP)

Trial Locations (12)

10003

NYU Langone Orthopedic Hospital, New York

19107

Rothman, Philadelphia

21215

LifeBridge, Baltimore

26501

WVU, Morgantown

34232

Gulfcoast Research, Sarasota

43203

Ohio State University, Columbus

44106

Cleveland Clinic, Cleveland

University of Utah Orthopaedic Center, Salt Lake City

77030

Memorial Hermann Hospital, Houston

Michael E. DeBakey VA Medical Center, Houston

94305

Stanford Hospital, Palo Alto

02115

Brigham & Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

collaborator

Wellcome Trust

OTHER

lead

Peptilogics

INDUSTRY

NCT05137314 - Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) | Biotech Hunter | Biotech Hunter